Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Pharmacyclics Incorporated (Nasdaq: PCYC) hit a new 52-week high Tuesday as it is currently trading at $71.94, above its previous 52-week high of $71.91 with 128,524 shares traded as of 10:26 a.m. ET. Average volume has been 552,000 shares over the past 30 days. Pharmacyclics has a market cap of $4.87 billion and is part of the health care sector and drugs industry. Shares are up 21% year to date as of the close of trading on Monday. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has a P/E ratio of 50, above the S&P 500 P/E ratio of 17.7.